Study documents safety, improvements from stem cell therapy after spinal cord injury
ROCHESTER, Minn. — A Mayo Clinic study shows stem cells derived from patients' own fat are safe and may improve sensation and movement after traumatic spinal cord injuries. The findings from the phase 1 clinical trial appear in Nature Communications. The results of this early research offer insights on the potenti al of cell therapy for people living with spinal cord injuries and paralysis for whom options to improve function are extremely limited. In the study… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - April 1, 2024 Category: Research Source Type: news
Uber, Axon Lead Five Stocks Near Buy Points
and Taser-maker Axon Enterprise (AXON) lead this weekend's watch list of five stocks near buy points. They're joined by Swiss athletic shoemaker On Holding (ONON), homebuilder M/I Homes (MHO) and Medpace Holdings (MEDP), which conducts clinical trials for biotech firms. The list features three…#taser #axonenterprise #axon #medpaceholdings #medp #ibdstockcheckup #ibdleaderboard #ibdlongtermleaders #truist #youssefsquali (Source: Reuters: Health)
Source: Reuters: Health - March 31, 2024 Category: Consumer Health News Source Type: news
AI-based Clinical Trials Solution Provider Market Report 2024-2034, Featuring CONSILX, AiCure, Unlearn.AI, Trials.Ai, Intelligencia, Symphony AI, GNS Healthcare, Verily, BioSymetrics & amp; BioAge Labs
DUBLIN, March 29, 2024 /PRNewswire/ -- The "Global AI-based Clinical Trials Solution Provider Market Analysis & Forecast to 2024-2034: Market By Clinical Trial Phase; By Therapeutic Application; By End-user; and By Region" report has been added to ResearchAndMarkets.com's offering. The... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 30, 2024 Category: Pharmaceuticals Tags: MRR Source Type: news
Genentech makes diversity, inclusion gains toward 2025 goals
The DEI report is far-reaching, covering the 10,000-employee biotech companies efforts in the workplace, among suppliers and in clinical trials. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 29, 2024 Category: Biotechnology Authors: Ron Leuty Source Type: news
Labcorp to pay $237.5M to acquire assets of BioReference Health's diagnostics business
Labcorp, the Burlington-based laboratory services company, has made five acquisitions since spinning off its clinical trials business last July. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 29, 2024 Category: Pharmaceuticals Authors: Daniel Finnegan Source Type: news
Drug Company's Libel Lawsuit Against Scientists Dismissed
From yesterday's decision by Judge Gregory Woods (S.D.N.Y.) in Cassava Sciences, Inc. v. Bredt: Cassava Sciences, Inc. ("Cassava") is a biotechnology company that is conducting clinical trials for an Alzheimer's drug called simufilam. Following the second phase of the simufilam clinical trials,…#gregorywoods #sdny #cassavasciencesinc #cassava #fda #firstamendment #plaintiff #defendants #defendant #magistrate (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2024 Category: Consumer Health News Source Type: news
NYU Langone begins histotripsy for liver cancer
NYU Langone Health’s Perlmutter Cancer Center is using histotripsy for some liver cancer cases, it said in a March 28 blog post.
Histotripsy uses focused ultrasound to deliver external beams intended to destroy cancerous tissue while leaving surrounding tissue intact. Histotripsy could become an option for patients who might otherwise be unlikely candidates for radiation or other ablation techniques, according to NYU Langone Health.
"This device allows us to offer ablation to patients who would normally not be good candidates," said Mikhail Silk, MD, an interventional radiologist at NYU Langone who performed the proced...
Source: AuntMinnie.com Headlines - March 29, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Eli Lilly in advanced clinical trials for its weight-loss pill
Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess its safety and efficacy compared to insulin glargine in individuals with type-two diabetes and obesity or overweight at an increased cardiovascular risk. The company's spokesperson in India mentioned ongoing clinical studies on novel products, including orforglipron. (Source: The Economic Times)
Source: The Economic Times - March 28, 2024 Category: Consumer Health News Source Type: news
Comparative analysis of CRASH and IMPACT in predicting the outcome of 340 patients with traumatic brain injury - An T, Dong Z, Li X, Ma Y, Jin J, Li L, Xu L.
BACKGROUND: Both the International Mission for Prognosis and Analysis of Clinical Trials (IMPACT) and the Corticosteroid randomization after significant head injury (CRASH) models are globally acknowledged prognostic algorithms for assessing traumatic brai... (Source: SafetyLit)
Source: SafetyLit - March 28, 2024 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Global and Regional MRD Testing Industry Report 2024: Market to Grow by $5 Billion During 2023-2033, Driven by Rising Number of Clinical Trials in Prolonged MRD-Negative Treatment Decisions
DUBLIN, March 27, 2024 /PRNewswire/ -- The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering. The MRD testing market was... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 27, 2024 Category: Pharmaceuticals Tags: MRR Source Type: news
Overcoming EU IVDR Challenges When Using Clinical Trial Assays to Accelerate Global CDx Trials, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about the challenges associated with the EU IVDR regulation. Attendees will gain insights into solutions to help overcome some IVDR hurdles for global clinical trials. The featured speakers will share key considerations when planning for CDx trials with EU... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 27, 2024 Category: Pharmaceuticals Tags: FVT TRI Source Type: news
Going Beyond ATS/ERS 2019 Guidelines for Your Respiratory Clinical Trials, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain valuable insights into the future of data quality assessment in respiratory drug development and learn how to leverage these advancements to drive success in respiratory clinical trials. The featured speakers will discuss the limitations of traditional adherence... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 27, 2024 Category: Pharmaceuticals Source Type: news
Brainomix touts e-Lung software clinical study results
U.K. AI software developer Brainomix highlighted a study that shows its e-Lung automated CT processing algorithm can stratify patients at risk of idiopathic pulmonary fibrosis (IPF).The study was an analysis of a completed phase II clinical trial by AstraZeneca of the company’s tralokinumab treatment in patients with idiopathic pulmonary fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool.e-Lung is powered by what is called the weighted reticulovascular score (WRVS), a biomarker that incorporates reticular opacities and vascular structures in assessments of the lung, Brainomix sai...
Source: AuntMinnie.com Headlines - March 27, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
FDA Approves Merck ’s New Drug For A Rare Lung Disease
The pharmaceutical giant ’s new treatment, sotatercept, showed significant benefits for the thousands of patients suffering from pulmonary arterial hypertension in clinical trials. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 26, 2024 Category: Pharmaceuticals Authors: Alex Knapp, Forbes Staff Tags: Science /science Innovation /innovation Healthcare /healthcare Editors' Pick editors-pick Premium Content premiumcontent technology alexknappblog Source Type: news
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. ZVRA (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2…#celebration #fla #zevra #phase2 #nct05668754 #kp1077 #zevraphase2 #ih #christopherdrake #phd (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2024 Category: Consumer Health News Source Type: news
